ArisGen SA
This article was originally published in Start Up
Executive Summary
ArisGen SA is tackling the two most persistent issues stymieing peptide drug development: overcoming the need for injection through an oral-delivery formulation and penetrating cell membranes to reach presently undruggable targets. The company has developed two unique platform technologies: a formulation series of precision polymers, which with appropriate excipients mask the active molecule’s functional groups allowing noninvasive drug absorption, and a reversible functionalization system enabling therapeutics to selectively penetrate across membrane barriers to reach the drug’s target inside the cell.
You may also be interested in...
Start-Up Previews (09/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Biotechs Target Cancer Metabolism," features profiles of Advanced Cancer Therapeutics, Cornerstone Pharmaceuticals and Dynamix Pharmaceuticals. Plus these Start-Ups Across Health Care: AlloCure, ArisGen, HistoSonics and NeuraviBiotechnology.
Start-Up Previews (09/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Biotechs Target Cancer Metabolism," features profiles of Advanced Cancer Therapeutics, Cornerstone Pharmaceuticals and Dynamix Pharmaceuticals. Plus these Start-Ups Across Health Care: AlloCure, ArisGen, HistoSonics and NeuraviBiotechnology.
Peptide Therapeutics' Rising Tide
As emerging technologies begin to overcome peptide therapeutics’ pharmacologic limitations, their compelling potential grows clearer and their deal value has grown. Most if not all of Big Pharma and Big Biotech now have rebuilt their internal peptide drug development programs and show interest in start-ups with peptide pipelines and platforms.